📊 SXTPW Key Takeaways
Is 60 Degrees Pharmaceuticals, Inc.. (SXTPW) a Good Investment?
60 Degrees Pharmaceuticals faces an imminent cash crisis with approximately 2-3 months of runway at current burn rates ($6.8M operating cash burn vs $1M revenue). Despite positive 65.5% YoY revenue growth, the company operates at severe losses with -771.6% operating margin, offering minimal fundamental support even for speculative biotech positions.
Why Buy 60 Degrees Pharmaceuticals, Inc.. Stock? SXTPW Key Strengths
- Revenue growth of 65.5% YoY signals early market traction
- Low debt-to-equity ratio of 0.04x provides balance sheet flexibility with minimal leverage
- Adequate short-term liquidity with current ratio of 2.66x
SXTPW Stock Risks: 60 Degrees Pharmaceuticals, Inc.. Investment Risks
- Critical cash burn: -$6.8M operating cash flow against only $1M revenue; approximately 2-3 months of cash runway remaining
- Unsustainable unit economics with -771.6% operating margin and -732.5% net margin
- Trivial revenue base of $1M from pharmaceutical operations creates execution risk in capital-intensive sector requiring significant R&D spend
- Zero insider Form 4 filings in last 90 days suggests lack of insider confidence
- High dilution risk if equity financing required to extend runway
Key Metrics to Watch
- Cash and equivalents level and projected runway; any decline below $1M is critical warning
- Quarterly revenue acceleration and gross margin sustainability
- Operating cash flow improvement toward breakeven; current -$6.8M burn rate is unsustainable
60 Degrees Pharmaceuticals, Inc.. (SXTPW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.66x current ratio provides a solid financial cushion.
SXTPW Profit Margin, ROE & Profitability Analysis
SXTPW vs Healthcare Sector: How 60 Degrees Pharmaceuticals, Inc.. Compares
How 60 Degrees Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is 60 Degrees Pharmaceuticals, Inc.. Stock Overvalued? SXTPW Valuation Analysis 2026
Based on fundamental analysis, 60 Degrees Pharmaceuticals, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
60 Degrees Pharmaceuticals, Inc.. Balance Sheet: SXTPW Debt, Cash & Liquidity
SXTPW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: 60 Degrees Pharmaceuticals, Inc..'s revenue has grown significantly by 297% over the 5-year period, indicating strong business expansion. The most recent EPS of $-74.17 indicates the company is currently unprofitable.
SXTPW Revenue Growth, EPS Growth & YoY Performance
SXTPW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $135.3K | -$2.2M | $-0.66 |
| Q2 2025 | $100.9K | -$1.7M | $-1.25 |
| Q1 2025 | $105.7K | $430.5K | $-1.56 |
| Q3 2024 | $51.2K | -$1.8M | $-0.93 |
| Q2 2024 | $59.5K | -$3.3M | $-4.23 |
| Q1 2024 | $17.2K | $430.5K | $0.03 |
| Q3 2023 | $51.2K | -$1.4M | $-0.55 |
| Q2 2023 | $45.2K | -$2.1M | $-0.96 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
60 Degrees Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
SXTPW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for 60 Degrees Pharmaceuticals, Inc.. (CIK: 0001946563)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SXTPW
What is the AI rating for SXTPW?
60 Degrees Pharmaceuticals, Inc.. (SXTPW) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SXTPW's key strengths?
Claude: Revenue growth of 65.5% YoY signals early market traction. Low debt-to-equity ratio of 0.04x provides balance sheet flexibility with minimal leverage.
What are the risks of investing in SXTPW?
Claude: Critical cash burn: -$6.8M operating cash flow against only $1M revenue; approximately 2-3 months of cash runway remaining. Unsustainable unit economics with -771.6% operating margin and -732.5% net margin.
What is SXTPW's revenue and growth?
60 Degrees Pharmaceuticals, Inc.. reported revenue of $1.0M.
Does SXTPW pay dividends?
60 Degrees Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find SXTPW SEC filings?
Official SEC filings for 60 Degrees Pharmaceuticals, Inc.. (CIK: 0001946563) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SXTPW's EPS?
60 Degrees Pharmaceuticals, Inc.. has a diluted EPS of $-11.73.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SXTPW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, 60 Degrees Pharmaceuticals, Inc.. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SXTPW stock overvalued or undervalued?
Valuation metrics for SXTPW: ROE of -212.7% (sector avg: 15%), net margin of -732.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SXTPW stock in 2026?
Our dual AI analysis gives 60 Degrees Pharmaceuticals, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SXTPW's free cash flow?
60 Degrees Pharmaceuticals, Inc..'s operating cash flow is $-6.8M, with capital expenditures of $139.9K. FCF margin is -695.1%.
How does SXTPW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -732.5% (avg: 12%), ROE -212.7% (avg: 15%), current ratio 2.66 (avg: 2).